4.8 Article

Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis

期刊

HEPATOLOGY
卷 73, 期 2, 页码 571-585

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.31256

关键词

-

资金

  1. NIH-NIAAA [U01 AA21788, R01 AA021171]
  2. NIH-NIDDK [R01 DK11378]
  3. ISCIII project [PI16/00043]
  4. European Regional Development Fund [2017-SGR-01281]
  5. Agencia de Gestio d'Ajuts Universitaris de Recerca [2017-SGR-01281]
  6. Chile-FONDECYT [1200227]

向作者/读者索取更多资源

The study found that the plasma concentration of extracellular vesicles (EVs) was significantly higher in patients with alcoholic hepatitis (AH), and the sphingolipid content in EVs was significantly enriched in AH patients. EV concentration correlated with the Model for End-Stage Liver Disease score, and the sphingolipid components of EVs showed good performance as biomarkers for the diagnosis and prognosis of AH.
Background and Aims Alcoholic hepatitis (AH) is diagnosed by clinical criteria, although several objective scores facilitate risk stratification. Extracellular vesicles (EVs) have emerged as biomarkers for many diseases and are also implicated in the pathogenesis of AH. Therefore, we investigated whether plasma EV concentration and sphingolipid cargo could serve as diagnostic biomarkers for AH and inform prognosis to permit dynamic risk profiling of AH subjects. Approach and Results EVs were isolated and quantified from plasma samples from healthy controls, heavy drinkers, and subjects with end-stage liver disease (ESLD) attributed to cholestatic liver diseases and nonalcoholic steatohepatitis, decompensated alcohol-associated cirrhosis (AC), and AH. Sphingolipids were quantified by tandem mass spectroscopy. The median plasma EV concentration was significantly higher in AH subjects (5.38 x 10(11)/mL) compared to healthy controls (4.38 x 10(10)/mL; P < 0.0001), heavy drinkers (1.28 x 10(11)/mL; P < 0.0001), ESLD (5.35 x 10(10)/mL; P < 0.0001), and decompensated AC (9.2 x 10(10)/mL; P < 0.0001) disease controls. Among AH subjects, EV concentration correlated with Model for End-Stage Liver Disease score. When EV counts were dichotomized at the median, survival probability for AH subjects at 90 days was 63.0% in the high-EV group and 90.0% in the low-EV group (log-rank P value = 0.015). Interestingly, EV sphingolipid cargo was significantly enriched in AH when compared to healthy controls, heavy drinkers, ESLD, and decompensated AC (P = 0.0001). Multiple sphingolipids demonstrated good diagnostic and prognostic performance as biomarkers for AH. Conclusions Circulating EV concentration and sphingolipid cargo signature can be used in the diagnosis and differentiation of AH from heavy drinkers, decompensated AC, and other etiologies of ESLD and predict 90-day survival permitting dynamic risk profiling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据